Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis

Aifang LIU, Lei LUO, Wenlong YANG

PDF(1353 KB)
PDF(1353 KB)
Journal of Clinical Hepatol ›› 2025, Vol. 41 ›› Issue (1) : 145-150. DOI: 10.12449/JCH250122
Review

Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis

Author information +
History +

Abstract

Metabolic dysfunction-associated steatotic liver disease is the largest liver disease around the world and is a serious public health hazard， but there has always been a lack of drugs approved for treatment. On March 14， 2024， Resmetirom became the first drug approved by the US Food and Drug Administration for the treatment of metabolic dysfunction-associated steatohepatitis （MASH）. This article summarizes the mechanism of action of Resmetirom in the treatment of MASH， related clinical trial designs， and some research results and analyzes shortcomings and future prospects. Current data have shown that Resmetirom is effective in improving steatohepatitis and liver fibrosis， but there is still a large gap between Resmetirom and the ideal drug for the treatment of MASH， and it is expected to develop more effective drugs for MASH.

Key words

Metabolic Dysfunction-Associated Steatohepatitis / Resmetirom / Clinical Trial

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Aifang LIU , Lei LUO , Wenlong YANG. Advances of clinical trials related to Resmetirom as an approved new drug for metabolic dysfunction-associated steatohepatitis. Journal of Clinical Hepatol. 2025, 41(1): 145-150 https://doi.org/10.12449/JCH250122

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
TARGHER G, BYRNE CD, TILG H. MASLD: A systemic metabolic disorder with cardiovascular and malignant complications[J]. Gut, 2024, 73(4): 691-702. DOI: 10.1136/gutjnl-2023-330595 .
本文引用 [1]
2
MIAO L, TARGHER G, BYRNE CD, et al. Current status and future trends of the global burden of MASLD[J]. Trends Endocrinol Metab, 2024, 35(8): 697-707. DOI: 10.1016/j.tem.2024.02.007 .
3
YIP TCF, FAN JG, WONG VWS. China’s fatty liver crisis: A looming public health emergency[J]. Gastroenterology, 2023, 165(4): 825-827. DOI: 10.1053/j.gastro.2023.06.008 .
本文引用 [1]
4
DIEHL AM, DAY C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377(21): 2063-2072. DOI: 10.1056/NEJMra1503519 .
本文引用 [1]
5
RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835. DOI: 10.1097/HEP.0000000000000323 .
本文引用 [2]
6
KOKKORAKIS M, BOUTARI C, HILL MA, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges[J]. Metabolism, 2024, 154: 155835. DOI: 10.1016/j.metabol.2024.155835 .
本文引用 [1]
7
TAUB R, CHIANG E, CHABOT-BLANCHET M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist[J]. Atherosclerosis, 2013, 230(2): 373-380. DOI: 10.1016/j.atherosclerosis.2013.07.056 .
本文引用 [1]
8
HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213): 2012-2024. DOI: 10.1016/S0140-6736(19)32517-6 .
本文引用 [1]
9
HARRISON SA, RATZIU V, ANSTEE QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2024, 59(1): 51-63. DOI: 10.1111/apt.17734 .
本文引用 [1]
10
HARRISON SA, BEDOSSA P, GUY CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6): 497-509. DOI: 10.1056/NEJMoa2309000 .
本文引用 [1]
11
HARRISON SA, TAUB R, NEFF GW, et al. Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial[J]. Nat Med, 2023, 29(11): 2919-2928. DOI: 10.1038/s41591-023-02603-1 .
本文引用 [1]
12
ClinicalTrials.gov. phaseA 3 study to evaluate safety and biomarkers of Resmetirom (MGL-3196) in patients with non-alcoholic fatty liver disease (NAFLD), MAESTRO-NAFLD-open-label-extension(MAESTRO-NAFLD-OLE)[EB/OL]. (2023-12-04)[2024-04-16].
https://clinicaltrials.gov/study/NCT04951219?term=NCT04951219&rank=1
本文引用 [1]
13
ClinicalTrials.gov. A phase 3 study to evaluate the effect of Resmetirom on clinical outcomes in patients with well-compensated NASH cirrhosis (MAESTRO-NASH-OUTCOMES)[EB/OL]. (2024-03-25)[2024-04-16].
https://clinicaltrials.gov/study/NCT05500222?term=NCT05500222&rank=1
本文引用 [1]
14
LEUNG PB, DAVIS AM, KUMAR S. Diagnosis and management of nonalcoholic fatty liver disease[J]. JAMA, 2023, 330(17): 1687-1688. DOI: 10.1001/jama.2023.17935 .
本文引用 [1]
15
ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149(2): 389-397. DOI: 10.1053/j.gastro.2015.04.043 .
本文引用 [1]
16
YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7 .
本文引用 [1]
17
ESLAM M, ALVANI R, SHIHA G. Obeticholic acid: Towards first approval for NASH[J]. Lancet, 2019, 394(10215): 2131-2133. DOI: 10.1016/S0140-6736(19)32963-0 .
本文引用 [1]
18
LUO L, ZOU H, ZHENG S, et al. Letter to the editor: Suggestions for rational management of nonalcoholic fatty liver disease[J]. Hepatology, 2019, 70(4): 1492-1493. DOI: 10.1002/hep.30797 .
本文引用 [1]
19
HARRISON SA, FRIAS JP, NEFF G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): A multicentre, randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(12): 1080-1093. DOI: 10.1016/S2468-1253(23)00272-8 .
本文引用 [1]
20
LOOMBA R, SANYAL AJ, KOWDLEY KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH[J]. N Engl J Med, 2023, 389(11): 998-1008. DOI: 10.1056/NEJMoa2304286 .
本文引用 [1]
21
NEWSOME PN, BUCHHOLTZ K, CUSI K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12): 1113-1124. DOI: 10.1056/NEJMoa2028395 .
本文引用 [1]
22
VIOLI F, CANGEMI R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med, 2010, 363(12): 1185-1186. DOI: 10.1056/NEJMc1006581 .
本文引用 [1]
23
The Lancet Gastroenterology Hepatology. Resmetirom for NASH: Balancing promise and prudence[J]. Lancet Gastroenterol Hepatol, 2024, 9(4): 273. DOI: 10.1016/S2468-1253(24)00049-9 .
本文引用 [1]
24
CUSI K. Selective agonists of thyroid hormone receptor beta for the treatment of NASH[J]. N Engl J Med, 2024, 390(6): 559-561. DOI: 10.1056/NEJMe2314365 .
本文引用 [1]
25
PETTA S, TARGHER G, ROMEO S, et al. The first MASH drug therapy on the horizon: Current perspectives of resmetirom[J]. Liver Int, 2024, 44(7): 1526-1536. DOI: 10.1111/liv.15930 .
本文引用 [1]

刘爱芳负责论文构思，设计及撰写；罗磊和杨文龙负责论文修订、指导、质量控制与审校。

Funding

PHD Startup Fund of the Second Affiliated Hospital of Nanchang University （B2273）

Comments

PDF(1353 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Clinical Hepatol, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉